亿腾上市迎新节点:嘉和生物递表港股

极目新闻
17 Jul

4月15日,嘉和生物向香港联交所递交上市申请,这一事件标志着港股18A规则下首例创新药企反向收购案例迎来重要进展。此次申请背后,是嘉和生物与亿腾医药的战略合并,合并上市后的新公司“亿腾嘉和”正以全新姿态,迈向资本市场的新征程。这场合并堪称一场共赢之举,双方优势互补,为新公司的发展奠定了坚实基础。嘉和生物以强大的研发实力著称,专注于肿瘤及自体免疫药物的开发及商业化。其拥有多特异性抗体创新药发现技术...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10